Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790730 | 1.00 | HTR7 (0.65) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL7492089 | 1.00 | HTR7 (0.65) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL7491493 | 0.93 | HTR7 (0.64) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL764669 | 0.85 | HTR2C (0.67) | HTR2AHTR2C | |
| SCHEMBL7491550 | 0.85 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL2504528 | 0.83 | HTR7 (0.61) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL5528826 | 0.83 | HTR7 (0.61) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL5532312 | 0.83 | HTR7 (0.61) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL14599797 | 0.83 | HTR7 (0.61) | HTR7DRD2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL30274351 | 0.82 | HTR2A (0.74) | HTR7DRD2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360186-B1 | CARBOLINE DERIVATIVES | LILLY ICOS LLC (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7122554-B2 | Carboline derivatives | LILLY ICOS LLC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1397361-B1 | CARBOLINE DERIVATIVES AS PDEV INHIBITORS | LILLY ICOS LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-7022856-B2 | Carboline derivatives | LILLY ICOS LLC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6992192-B2 | Carboline derivatives as PDE5 inhibitors | LILLY ICOS LLC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6984641-B2 | Carboline derivatives as PDE5 inhibitors | LILLY ICOS LLC. (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1360185-B1 | CARBOLINE DERIVATIVES | LILLY ICOS LLC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| US-6864253-B2 | Benzo[4,5]thieno[2,3-c]pyridine and Benzo[4,5]furo[2,3-c]pyridine Derivatives Useful as Inhibitors of Phosphodiesterase | ORTH-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20050026941-A1 | Carboline derivatives as pde-5 inhibitors | LILLY ICOS LLC | 2005-02-03 | — | — | US | disclosed |
| US-20030166641-A1 | Beta-carboline derivatives useful as inhibitors of phosphodiesterase | SUI ZHIHUA (US) | 2003-09-04 | — | — | US | disclosed |
| US-6492358-B2 | FOR TREATMENT OF SEXUAL DISORDERS, MALE ERECTILE DYSFUNCTION | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6462047-B1 | CONTAINING 5- OR 6-MEMBERED OXYGEN, NITROGEN AND/OR SULFUR HETEROARYL GROUP; ANGINA, HYPERTENSION, RESPIRATORY DISTRESS, CONGESTIVE HEART FAILURE, RENAL FAILURE, ATHEROSCLEROSIS, INFLAMMATORY DISEASES, STROKES, BRONCHITIS, ASTHMA | ICOS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-20020072055-A1 | Iterative and regenerative DNA sequencing method | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-06-13 | — | — | US | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020010189-A1 | beta-carboline derivatives useful as inhibitors of phosphodiesterase | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | HTR7 1769/4885DRD2 2349/4885CHRM4 2211/4885 |
| US-20050026941-A1 | Carboline derivatives as pde-5 inhibitors | PDE5A, PDE3B, PDE3A | HTR7 709/4885DRD2 502/4885CHRM4 627/4885 |
| US-20020010189-A1 | beta-carboline derivatives useful as inhibitors of phosphodiesterase | PDE3B, PDE5A, PDE3A | HTR7 1337/4885DRD2 515/4885CHRM4 905/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | HTR7 1742/4885DRD2 2479/4885CHRM4 2053/4885 |
| US-20030166641-A1 | Beta-carboline derivatives useful as inhibitors of phosphodiesterase | PDE3B, PDE5A, PDE3A | HTR7 1337/4885DRD2 515/4885CHRM4 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.